Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

David A Kass, Edward Shapiro, M. Kawaguchi, A. R. Capriotti, A. Scuteri, R. C. DeGroof, Edward Lakatta

Research output: Contribution to journalArticle

Abstract

Background - Arterial stiffening with increased pulse pressure is a leading risk factor for cardiovascular disease in the elderly. We tested whether ALT-711, a novel nonenzymatic breaker of advanced glycation end-product crosslinks, selectively improves arterial compliance and lowers pulse pressure in older individuals with vascular stiffening. Methods and Results - Nine US centers recruited and randomly assigned subjects with resting arterial pulse pressures >60 mm Hg and systolic pressures >140 mm Hg to once-daily ALT-711 (210 mg; n=62) or placebo (n=31) for 56 days. Preexisting antihypertensive treatment (90% of subjects) was continued during the study. Morning upright blood pressure, stroke volume, cardiac output, systemic vascular resistance, total arterial compliance, carotid-femoral pulse wave velocity, and drug tolerability were assessed. ALT-711 netted a greater decline in pulse pressures than placebo (-5.3 versus -0.6 mm Hg at day 56; P=0.034 for treatment effect by repeated-measures ANOVA). Systolic pressure declined in both groups, but diastolic pressure fell less with ALT-711 (P=0.056). Mean pressure declined similarly in both groups (-4 mm Hg; P

Original languageEnglish (US)
Pages (from-to)1464-1470
Number of pages7
JournalCirculation
Volume104
Issue number13
StatePublished - Sep 25 2001

Fingerprint

Advanced Glycosylation End Products
Compliance
Blood Pressure
Placebos
Pulse Wave Analysis
Thigh
Cardiac Output
Vascular Resistance
Stroke Volume
Antihypertensive Agents
Blood Vessels
Analysis of Variance
Arterial Pressure
Cardiovascular Diseases
Pressure
alagebrium
Therapeutics

Keywords

  • Aging
  • ALT-711
  • Arteries
  • Compliance
  • Glycosylation end products, advanced
  • Hypertension

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Kass, D. A., Shapiro, E., Kawaguchi, M., Capriotti, A. R., Scuteri, A., DeGroof, R. C., & Lakatta, E. (2001). Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation, 104(13), 1464-1470.

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. / Kass, David A; Shapiro, Edward; Kawaguchi, M.; Capriotti, A. R.; Scuteri, A.; DeGroof, R. C.; Lakatta, Edward.

In: Circulation, Vol. 104, No. 13, 25.09.2001, p. 1464-1470.

Research output: Contribution to journalArticle

Kass, DA, Shapiro, E, Kawaguchi, M, Capriotti, AR, Scuteri, A, DeGroof, RC & Lakatta, E 2001, 'Improved arterial compliance by a novel advanced glycation end-product crosslink breaker', Circulation, vol. 104, no. 13, pp. 1464-1470.
Kass DA, Shapiro E, Kawaguchi M, Capriotti AR, Scuteri A, DeGroof RC et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001 Sep 25;104(13):1464-1470.
Kass, David A ; Shapiro, Edward ; Kawaguchi, M. ; Capriotti, A. R. ; Scuteri, A. ; DeGroof, R. C. ; Lakatta, Edward. / Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. In: Circulation. 2001 ; Vol. 104, No. 13. pp. 1464-1470.
@article{04cdc03d684c4e84890e43f17a44d92a,
title = "Improved arterial compliance by a novel advanced glycation end-product crosslink breaker",
abstract = "Background - Arterial stiffening with increased pulse pressure is a leading risk factor for cardiovascular disease in the elderly. We tested whether ALT-711, a novel nonenzymatic breaker of advanced glycation end-product crosslinks, selectively improves arterial compliance and lowers pulse pressure in older individuals with vascular stiffening. Methods and Results - Nine US centers recruited and randomly assigned subjects with resting arterial pulse pressures >60 mm Hg and systolic pressures >140 mm Hg to once-daily ALT-711 (210 mg; n=62) or placebo (n=31) for 56 days. Preexisting antihypertensive treatment (90{\%} of subjects) was continued during the study. Morning upright blood pressure, stroke volume, cardiac output, systemic vascular resistance, total arterial compliance, carotid-femoral pulse wave velocity, and drug tolerability were assessed. ALT-711 netted a greater decline in pulse pressures than placebo (-5.3 versus -0.6 mm Hg at day 56; P=0.034 for treatment effect by repeated-measures ANOVA). Systolic pressure declined in both groups, but diastolic pressure fell less with ALT-711 (P=0.056). Mean pressure declined similarly in both groups (-4 mm Hg; P",
keywords = "Aging, ALT-711, Arteries, Compliance, Glycosylation end products, advanced, Hypertension",
author = "Kass, {David A} and Edward Shapiro and M. Kawaguchi and Capriotti, {A. R.} and A. Scuteri and DeGroof, {R. C.} and Edward Lakatta",
year = "2001",
month = "9",
day = "25",
language = "English (US)",
volume = "104",
pages = "1464--1470",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

AU - Kass, David A

AU - Shapiro, Edward

AU - Kawaguchi, M.

AU - Capriotti, A. R.

AU - Scuteri, A.

AU - DeGroof, R. C.

AU - Lakatta, Edward

PY - 2001/9/25

Y1 - 2001/9/25

N2 - Background - Arterial stiffening with increased pulse pressure is a leading risk factor for cardiovascular disease in the elderly. We tested whether ALT-711, a novel nonenzymatic breaker of advanced glycation end-product crosslinks, selectively improves arterial compliance and lowers pulse pressure in older individuals with vascular stiffening. Methods and Results - Nine US centers recruited and randomly assigned subjects with resting arterial pulse pressures >60 mm Hg and systolic pressures >140 mm Hg to once-daily ALT-711 (210 mg; n=62) or placebo (n=31) for 56 days. Preexisting antihypertensive treatment (90% of subjects) was continued during the study. Morning upright blood pressure, stroke volume, cardiac output, systemic vascular resistance, total arterial compliance, carotid-femoral pulse wave velocity, and drug tolerability were assessed. ALT-711 netted a greater decline in pulse pressures than placebo (-5.3 versus -0.6 mm Hg at day 56; P=0.034 for treatment effect by repeated-measures ANOVA). Systolic pressure declined in both groups, but diastolic pressure fell less with ALT-711 (P=0.056). Mean pressure declined similarly in both groups (-4 mm Hg; P

AB - Background - Arterial stiffening with increased pulse pressure is a leading risk factor for cardiovascular disease in the elderly. We tested whether ALT-711, a novel nonenzymatic breaker of advanced glycation end-product crosslinks, selectively improves arterial compliance and lowers pulse pressure in older individuals with vascular stiffening. Methods and Results - Nine US centers recruited and randomly assigned subjects with resting arterial pulse pressures >60 mm Hg and systolic pressures >140 mm Hg to once-daily ALT-711 (210 mg; n=62) or placebo (n=31) for 56 days. Preexisting antihypertensive treatment (90% of subjects) was continued during the study. Morning upright blood pressure, stroke volume, cardiac output, systemic vascular resistance, total arterial compliance, carotid-femoral pulse wave velocity, and drug tolerability were assessed. ALT-711 netted a greater decline in pulse pressures than placebo (-5.3 versus -0.6 mm Hg at day 56; P=0.034 for treatment effect by repeated-measures ANOVA). Systolic pressure declined in both groups, but diastolic pressure fell less with ALT-711 (P=0.056). Mean pressure declined similarly in both groups (-4 mm Hg; P

KW - Aging

KW - ALT-711

KW - Arteries

KW - Compliance

KW - Glycosylation end products, advanced

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=0035949502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035949502&partnerID=8YFLogxK

M3 - Article

C2 - 11571237

AN - SCOPUS:0035949502

VL - 104

SP - 1464

EP - 1470

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 13

ER -